Does tumour dormancy offer a therapeutic target? (original) (raw)

• Weiss, L. Metastatic inefficiency. Adv. Cancer Res. 54, 159–211 (1990).
  Article CAS Google Scholar
• Chambers, A. F., Groom, A. C. & MacDonald, I. C. Dissemination and growth of cancer cells in metastatic sites. Nature Rev. Cancer 2, 563–572 (2002).
  Article CAS Google Scholar
• Heyn, C. et al. In vivo MRI of cancer cell fate at the single-cell level in a mouse model of breast cancer metastasis to the brain. Magn. Reson. Med. 56, 1001–1010 (2006).
  Article Google Scholar
• Townson, J. L. et al. Three-dimensional imaging and quantification of both solitary cells and metastases in whole mouse liver by magnetic resonance imaging. Cancer Res. 69, 8326–8331 (2009).
  Article CAS Google Scholar
• Luzzi, K. J. et al. Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am. J. Pathol. 153, 865–873 (1998).
  Article CAS Google Scholar
• Naumov, G. N. et al. Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy. Cancer Res. 62, 2162–2168 (2002).
  CAS PubMed Google Scholar
• Cameron, M. D. et al. Temporal progression of metastasis in lung: cell survival, dormancy, and location dependence of metastatic inefficiency. Cancer Res. 60, 2541–2546 (2000).
  CAS PubMed Google Scholar
• Holmgren, L., O'Reilly, M. S. & Folkman, J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med. 1, 149–153 (1995).
  Article CAS Google Scholar
• Aguirre-Ghiso, J. A. Models, mechanisms and clinical evidence for cancer dormancy. Nature Rev. Cancer 7, 834–846 (2007).
  Article CAS Google Scholar
• Muller, V., Alix-Panabieres, C. & Pantel, K. Insights into minimal residual disease in cancer patients: implications for anti-cancer therapies. Eur. J. Cancer 46, 1189–1197 (2010).
  Article Google Scholar
• Pantel, K., Alix-Panabieres, C. & Riethdorf, S. Cancer micrometastases. Nature Rev. Clin. Oncol. 6, 339–351 (2009).
  CAS Google Scholar
• Naumov, G. N. et al. A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J. Natl Cancer Inst. 98, 316–325 (2006).
  Article Google Scholar
• Naumov, G. N., Akslen, L. A. & Folkman, J. Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle 5, 1779–1787 (2006).
  Article CAS Google Scholar
• Indraccolo, S., Favaro, E. & Amadori, A. Dormant tumors awaken by a short-term angiogenic burst: the spike hypothesis. Cell Cycle 5, 1751–1755 (2006).
  Article CAS Google Scholar
• Favaro, E., Amadori, A. & Indraccolo, S. Cellular interactions in the vascular niche: implications in the regulation of tumor dormancy. APMIS 116, 648–659 (2008).
  Article CAS Google Scholar
• Indraccolo, S. et al. Cross-talk between tumor and endothelial cells involving the Notch3-Dll4 interaction marks escape from tumor dormancy. Cancer Res. 69, 1314–1323 (2009).
  Article CAS Google Scholar
• Ranganathan, A. C., Adam, A. P., Zhang, L. & Aguirre-Ghiso, J. A. Tumor cell dormancy induced by p38SAPK and ER-stress signaling: an adaptive advantage for metastatic cells? Cancer Biol. Ther. 5, 729–735 (2006).
  Article CAS Google Scholar
• Allgayer, H. & Aguirre-Ghiso, J. A. The urokinase receptor (u-PAR)-a link between tumor cell dormancy and minimal residual disease in bone marrow? APMIS 116, 602–614 (2008).
  Article CAS Google Scholar
• Adam, A. P. et al. Computational identification of a p38SAPK-regulated transcription factor network required for tumor cell quiescence. Cancer Res. 69, 5664–5672 (2009).
  Article CAS Google Scholar
• Rak, J. W., McEachern, D. & Miller, F. R. Sequential alteration of peanut agglutinin binding-glycoprotein expression during progression of murine mammary neoplasia. Br. J. Cancer 65, 641–648 (1992).
  Article CAS Google Scholar
• Morris, V. L., Tuck, A. B., Wilson, S. M., Percy, D. & Chambers, A. F. Tumor progression and metastasis in murine D2 hyperplastic alveolar nodule mammary tumor cell lines. Clin. Exp. Metastasis 11, 103–112 (1993).
  Article CAS Google Scholar
• Naumov, G. N. et al. Ineffectiveness of doxorubicin treatment on solitary dormant mammary carcinoma cells or late-developing metastases. Breast Cancer Res. Treat. 82, 199–206 (2003).
  Article CAS Google Scholar
• Barkan, D. et al. Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton. Cancer Res. 68, 6241–6250 (2008).
  Article CAS Google Scholar
• Barkan, D. et al. Metastatic growth from dormant cells induced by a Col-I-enriched fibrotic environment. Cancer Res. 70, 5706–5716 (2010).
  Article CAS Google Scholar
• Barkan, D., Green, J. E. & Chambers, A. F. Extracellular matrix: a gatekeeper in the transition from dormancy to metastatic growth. Eur. J. Cancer 46, 1181–1188 (2010).
  Article CAS Google Scholar
• Shibue, T. & Weinberg, R. A. Integrin β1-focal adhesion kinase signaling directs the proliferation of metastatic cancer cells disseminated in the lungs. Proc. Natl Acad. Sci. USA 106, 10290–10295 (2009).
  Article CAS Google Scholar
• Goodison, S. et al. Prolonged dormancy and site-specific growth potential of cancer cells spontaneously disseminated from nonmetastatic breast tumors as revealed by labeling with green fluorescent protein. Clin. Cancer Res. 9, 3808–3814 (2003).
  CAS PubMed Google Scholar
• Suzuki, M., Mose, E. S., Montel, V. & Tarin, D. Dormant cancer cells retrieved from metastasis-free organs regain tumorigenic and metastatic potency. Am. J. Pathol. 169, 673–681 (2006).
  Article CAS Google Scholar
• Husemann, Y. et al. Systemic spread is an early step in breast cancer. Cancer Cell 13, 58–68 (2008).
  PubMed Google Scholar
• Eyles, J. et al. Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. J. Clin. Invest. 120, 2030–2039 (2010).
  Article CAS Google Scholar
• Meng, S. et al. Circulating tumor cells in patients with breast cancer dormancy. Clin. Cancer Res. 10, 8152–8162 (2004).
  Article Google Scholar
• Sargent, D. J. et al. End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. J. Clin. Oncol. 25, 4569–4574 (2007).
  Article Google Scholar
• Saphner, T., Tormey, D. C. & Gray, R. Annual hazard rates of recurrence for breast cancer after primary therapy. J. Clin. Oncol. 14, 2738–2746 (1996).
  Article CAS Google Scholar
• Retsky, M. W., Demicheli, R., Hrushesky, W. J., Baum, M. & Gukas, I. D. Dormancy and surgery-driven escape from dormancy help explain some clinical features of breast cancer. APMIS 116, 730–741 (2008).
  Article CAS Google Scholar
• Hanin, L. & Korosteleva, O. Does extirpation of the primary breast tumor give boost to growth of metastases? Evidence revealed by mathematical modeling. Math. Biosci. 223, 133–141 (2010).
  Article Google Scholar
• Riethmuller, G. & Klein, C. A. Early cancer cell dissemination and late metastatic relapse: clinical reflections and biological approaches to the dormancy problem in patients. Semin. Cancer Biol. 11, 307–311 (2001).
  Article CAS Google Scholar
• Demicheli, R., Terenziani, M. & Bonadonna, G. Estimate of tumor growth time for breast cancer local recurrences: rapid growth after wake-up? Breast Cancer Res. Treat. 51, 133–137 (1998).
  Article CAS Google Scholar
• Braun, S. et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N. Engl. J. Med. 353, 793–802 (2005).
  Article CAS Google Scholar
• Ragaz, J. et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N. Engl. J. Med. 337, 956–962 (1997).
  Article CAS Google Scholar
• Overgaard, M. et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N. Engl. J. Med. 337, 949–955 (1997).
  Article CAS Google Scholar
• Slade, M. J. et al. Comparison of bone marrow, disseminated tumour cells and blood-circulating tumour cells in breast cancer patients after primary treatment. Br. J. Cancer 100, 160–166 (2009).
  Article CAS Google Scholar
• Wikman, H., Vessella, R. & Pantel, K. Cancer micrometastasis and tumour dormancy. APMIS 116, 754–770 (2008).
  Article CAS Google Scholar
• Flores, L. M. et al. Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer. Br. J. Cancer 102, 1495–1502 (2010).
  Article CAS Google Scholar
• Maheswaran, S. et al. Detection of mutations in EGFR in circulating lung-cancer cells. N. Engl. J. Med. 359, 366–377 (2008).
  Article CAS Google Scholar
• Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000).
  Article CAS Google Scholar
• Pantel, K. & Brakenhoff, R. H. Dissecting the metastatic cascade. Nature Rev. Cancer 4, 448–456 (2004).
  Article CAS Google Scholar
• Kendal, W. S. Chance mechanisms affecting the burden of metastases. BMC Cancer 5, 138 (2005).
  Article Google Scholar
• Chambers, A. F. Influence of diet on metastasis and tumor dormancy. Clin. Exp. Metastasis 26, 61–66 (2009).
  Article CAS Google Scholar
• Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687–1717 (2005).
• Fisher, B. et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J. Natl Cancer Inst. 88, 1529–1542 (1996).
  Article CAS Google Scholar
• Fisher, B., Dignam, J., Bryant, J. & Wolmark, N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J. Natl Cancer Inst. 93, 684–690 (2001).
  Article CAS Google Scholar
• Stewart, H. J. et al. Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group. Br. J. Cancer 74, 297–299 (1996).
  Article CAS Google Scholar
• Tormey, D. C., Gray, R. & Falkson, H. C. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group. J. Natl Cancer Inst. 88, 1828–1833 (1996).
  Article CAS Google Scholar
• Delozier, T. et al. Delayed adjuvant tamoxifen: ten-year results of a collaborative randomized controlled trial in early breast cancer (TAM-02 trial). Ann. Oncol. 11, 515–519 (2000).
  Article CAS Google Scholar
• Goss, P. E. et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N. Engl. J. Med. 349, 1793–1802 (2003).
  Article CAS Google Scholar
• Goss, P. E. et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J. Natl Cancer Inst. 97, 1262–1271 (2005).
  Article CAS Google Scholar
• Goss, P. E. et al. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J. Clin. Oncol. 26, 1948–1955 (2008).
  Article CAS Google Scholar
• Sabnis, G., Goloubeva, O., Gilani, R., Macedo, L. & Brodie, A. Sensitivity to the aromatase inhibitor letrozole is prolonged after a “break” in treatment. Mol. Cancer Ther. 9, 46–56 (2010).
  Article CAS Google Scholar
• Moy, B. & Goss, P. E. TEACH: Tykerb evaluation after chemotherapy. Clin. Breast Cancer 7, 489–492 (2007).
  Article CAS Google Scholar
• Tsao, H., Cosimi, A. B. & Sober, A. J. Ultra-late recurrence (15 years or longer) of cutaneous melanoma. Cancer 79, 2361–2370 (1997).
  Article CAS Google Scholar
• Farrar, J. D. et al. Cancer dormancy. VII. A regulatory role for CD8+ T cells and IFN-γ in establishing and maintaining the tumor-dormant state. J. Immunol. 162, 2842–2849 (1999).
  CAS PubMed Google Scholar
• Muller-Hermelink, N. et al. TNFR1 signaling and IFN-γ signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. Cancer Cell 13, 507–518 (2008).
  Article Google Scholar
• Quesnel, B. Tumor dormancy and immunoescape. APMIS 116, 685–694 (2008).
  Article Google Scholar
• Zhu, D., Corral, L. G., Fleming, Y. W. & Stein, B. Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol. Immunother. 57, 1849–1859 (2008).
  Article CAS Google Scholar
• Delea, T. E. et al. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer. Am. J. Manag. Care 12, 374–386 (2006).
  PubMed Google Scholar
• Chapman, J. A. et al. Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer. J. Natl Cancer Inst. 100, 252–260 (2008).
  Article Google Scholar
• Whelan, T. J. et al. Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J. Clin. Oncol. 23, 6931–6940 (2005).
  Article CAS Google Scholar
• Pantel, K., Braun, S., Schlimok, G. & Riethmuller, G. Micrometastatic tumour cells in bone marrow in colorectal cancer. Lancet 341, 501 (1993).
  Article CAS Google Scholar
• Pantel, K. et al. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J. Natl Cancer Inst. 85, 1419–1424 (1993).
  Article CAS Google Scholar
• Murphy, J. E. & Ryan, D. P. American Society of Clinical Oncology 2010 colorectal update. Expert Rev. Anticancer Ther. 10, 1371–1373 (2010).
  Article Google Scholar
• Allegra, C. J. et al. Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J. Clin. Oncol. 27, 3385–3390 (2009).
  Article CAS Google Scholar
• Wolmark, N. et al. A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: results of NSABP Protocol C-08. J. Clin. Oncol. Abstr. 27, LBA4 (2009).
  Article Google Scholar